breast cancer

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
Pharmaforum
Wed, 04/10/19 - 09:46 am
AstraZeneca
Merck
Lynparza
BRCA-mutant breast cancer
Europe
breast cancer
AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
Yahoo/Reuters
Fri, 03/29/19 - 10:06 am
AstraZeneca
Daiichi Sankyo
breast cancer
trastuzumab deruxtecan
New Study Says Breast Cancer Is 11 Different Diseases, Allowing Researchers To Predict Relapse
Forbes
Thu, 03/14/19 - 11:06 pm
breast cancer
Roche wins US approval of more convenient Herceptin
Biopharma Dive
Sat, 03/2/19 - 12:03 am
Roche
Herceptin
breast cancer
Pfizer launches China's first pay-for-performance model for cancer
BioCentury
Sat, 01/26/19 - 11:43 am
Pfizer
China
breast cancer
palbociclib
pay-for-performance
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
Stat
Fri, 01/18/19 - 12:12 am
Immunomedics
FDA
breast cancer
sacituzumab govitecan
Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio
Fierce Pharma
Fri, 01/18/19 - 12:09 am
Eli Lilly
NICE
Verzenio
breast cancer
Novartis Defends Itself Against Kickback Allegations from Former Employee
BioSpace
Thu, 01/10/19 - 09:57 am
Novartis
kickbacks
whistleblower lawsuits
breast cancer
New Class of Breast Cancer Drugs Could Help Treat Toughest Lung Cancer Cases
BioSpace
Fri, 12/28/18 - 01:30 pm
breast cancer
lung cancer
AstraZeneca
Tagrisso
Novartis
Gleevec
Tasigna
Bristol-Myers Squibb
Sprycel
Pfizer
Bosulif
Takeda
Iclusig
Novartis sheds light on liquid biopsies with SOLAR-1 analysis
Biopharma Dive
Fri, 12/7/18 - 12:03 pm
Novartis
alpelisib
breast cancer
liquid biopsy
Here's Why Puma Biotechnology Tanked 37.3% in November
Motley Fool
Fri, 12/7/18 - 10:46 am
Puma Biotechnology
Nerlynx
breast cancer
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
Mon, 11/19/18 - 11:29 am
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Pfizer works to get 'wait-and-see' doctors on board the Ibrance train
Fierce Pharma
Fri, 10/26/18 - 11:55 am
Pfizer
Ibrance
physicians
breast cancer
Not So Fast With Immune Therapy For Breast Cancer
Forbes
Mon, 10/22/18 - 11:14 pm
breast cancer
immunotherapy
Roche
Novartis wants to blaze a trail in breast cancer with PIK3 drug
Pharmaforum
Sun, 10/21/18 - 11:26 pm
Novartis
clinical trials
alpelisib
breast cancer
ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients
Fierce Biotech
Sat, 10/20/18 - 11:10 pm
Europe
Novartis
ESMO
AstraZeneca
breast cancer
BYL719
Benefit of Roche's Tecentriq looks limited in breast cancer
Biopharma Dive
Sat, 10/20/18 - 11:01 pm
Roche
Tecentriq
breast cancer
triple negative breast cancer
NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir
Fierce Pharma
Sat, 10/20/18 - 10:37 pm
Lilly
Verzenio
breast cancer
Pfizer
Ibrance
Novartis
Kisqali
NICE
Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?
Fierce Pharma
Thu, 10/18/18 - 12:15 am
Pfizer
breast cancer
PARP inhibitors
Talzenna
FDA approves Pfizer's drug for advanced breast cancer
Reuters
Tue, 10/16/18 - 08:40 pm
FDA
Pfizer
PARP inhibitors
talazoparib
breast cancer
BRCA-mutant breast cancer

Pages